Advertisement

American Journal of Clinical Dermatology

, Volume 20, Issue 2, pp 307–310 | Cite as

American Academy of Dermatology Annual Meeting: Washington, DC, USA, 1–5 March 2019

  • Kathy A. FraserEmail author
Meeting Report

This year’s annual meeting of the American Academy of Dermatology attracted over 18,000 attendees, and included over 480 educational sessions from international leaders in the field of dermatology. Here I report on just a few of the new drugs, developments and research that were discussed.

What’s New in Atopic Dermatitis?

In his presentation on “New and Emerging Therapies for Atopic Dermatitis”, Dr David Cohen (New York University School of Medicine, NY, USA) discussed a number of the biologics and Janus kinase (JAK) inhibitors that are currently under development for atopic dermatitis, including lebrikizumab and tralokinumab [both anti-interleukin (IL)-13 monoclonal antibodies (mAb)], nemolizumab (an IL-31 receptor inhibitor mAb), baricitinib (a JAK1/2 inhibitor), upadacitinib and PF-04965842 (both JAK1 inhibitors), and ASN002 (a JAK/SYK inhibitor).

Dupilumab

Dupilumab was approved in the USA for use in adults with atopic dermatitis in March 2017. The results of a pivotal phase 3...

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Kathy Fraser is a salaried employee of Adis/Springer and declares no relevant conflicts of interest.

References

  1. 1.
    Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–41.  https://doi.org/10.1016/j.jaci.2018.05.029 (Epub 2018 Jun 12).CrossRefGoogle Scholar
  2. 2.
    Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2018.  https://doi.org/10.1016/j.jaad.2018.01.018 (Epub ahead of print).Google Scholar
  3. 3.
    Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–286.e10.  https://doi.org/10.1016/j.jaad.2018.03.037 (Epub 2018 Mar 30).CrossRefGoogle Scholar
  4. 4.
    Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–314.e6.  https://doi.org/10.1016/j.jaad.2018.04.012 (Epub 2018 Apr 13).CrossRefGoogle Scholar
  5. 5.
    Gordon K, Reich K, Blauvelt A, et al. Certolizumab pegol for plaque psoriasis: two-year efficacy results from two phase 3 trials (CIMPASI-1 AND CIMPASI-2). Poster 8063. American Academy of Dermatology Annual Meeting, Washington, DC, Mar 1–5; 2019.Google Scholar
  6. 6.
    Ryan C, Crowley J, Valdecantos WC, et al. Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis. Poster 8110. American Academy of Dermatology Annual Meeting, Washington, DC, Mar 1–5; 2019.Google Scholar
  7. 7.
    Cartwright M, Mazzetti A, Moro L, Gerloni M. Pharmacokinetic profile, safety, and tolerability of clascoterone topical cream 1% in subjects with moderate-to-severe acne vulgaris: an open-label phase IIa study. Poster 10066. American Academy of Dermatology Annual Meeting, Washington, DC, Mar 1–5; 2019.Google Scholar
  8. 8.
    Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;1:1.  https://doi.org/10.1016/j.jaad.2019.02.044 (Epub ahead of print).Google Scholar
  9. 9.
    Blume-Peytavi U, Tanghetti E, Kemény L, et al. A long-term safety and efficacy study of trifarotene 50 μg/g cream in subjects with facial and truncal acne vulgaris. Poster 10074. American Academy of Dermatology Annual Meeting, Washington, DC, Mar 1–5; 2019.Google Scholar
  10. 10.
    Deeks ED. Sarecycline: first global approval. Drugs. 2019;79:325.  https://doi.org/10.1007/s40265-019-1053-4.CrossRefGoogle Scholar
  11. 11.
    Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987–96.Google Scholar
  12. 12.
    Gastman BR, Gerami P, Kurley SJ, et al. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80(1):149–157.e4.CrossRefGoogle Scholar
  13. 13.
    Ferris LK, Jansen B, Ho J, et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. JAMA Dermatol. 2017;153(7):675–80.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Adis PublicationsAucklandNew Zealand

Personalised recommendations